Surgeons in China reported transplanting a genetically modified pig liver segment into a patient with a liver tumor, marking what researchers describe as the first case of a xenogeneic liver graft functioning in a human. The pig segment supported metabolic activity for 38 days before removal due to thrombotic microangiopathy; the patient survived an additional 133 days and later died of gastrointestinal bleeding, the authors reported in the Journal of Hepatology. Investigators detailed immediate graft function — bile secretion and production of albumin and clotting factors — and chronic immune and coagulation complications that emerged in the second month, managed with immunosuppression and plasma exchange. The team framed the auxiliary graft as a bridge to recovery or to an orthotopic human transplant in cases of insufficient native liver reserve. Xenotransplantation observers said the case demonstrates functional feasibility but also highlights immunologic and hemostatic hurdles that must be resolved before broader clinical adoption.